Hyeong-Reh Kim, Ph.D.

Hyeong-Reh Kim, Ph.D.

Professor, Vice Dean of Research

313-577-2407 (Pathology Office), 313-577-9553 (VDR Office)

hrckim@med.wayne.edu

Hyeong-Reh Kim, Ph.D.

Address

9271 Scott Hall 540 E. Canfield Ave. Detroit, MI 48201

Office address

9271 Scott Hall
540 E. Canfield Ave.
Detroit, MI 48201

Department

 Pathology

Research interests

Dr. Kim’s research is centered on defining the molecular and cellular mechanisms by which proteolytic processing and growth factor signaling networks orchestrate tumor progression, metastasis, and therapeutic resistance. Her laboratory has made seminal contributions to elucidating isoform-specific platelet-derived growth factor (PDGF) signaling, particularly PDGF C and D, demonstrating that their activation by serine proteases such as uPA and matriptase represents a critical regulatory step that drives tumor-stromal interactions essential for tumor invasion and metastasis. Dr. Kim’s group further uncovered a novel PDGF D-initiated protease/growth factor signaling axis that regulates bone marrow mesenchymal stem cell differentiation and bone remodeling, thereby promoting intraosseous prostate cancer growth. These studies have revealed distinct signaling functions of PDGF D intermediates and identified PDGF D and matriptase as actionable therapeutic targets and potential biomarkers.

In parallel, Dr. Kim has elucidated the pleiotropic functions of TIMP-1 in cancer progression, identifying CD63 as its first cell surface receptor and establishing its role in integrin β1-mediated survival signaling and epithelial-mesenchymal transition.

Building on these discoveries, Dr. Kim’s recent work expands into cancer metabolism, where her team has identified lipid droplet-stored polyunsaturated fatty acids as a critical metabolic vulnerability in cancer cells. Her laboratory has demonstrated a novel mechanism to induce ferroptotic cell death and autophagy in therapy-resistant tumors by mobilizing intracellular lipid stores and degrading key anti-ferroptotic regulators. More broadly, Dr. Kim’s research has advanced the understanding of multiple programmed cell death pathways, including apoptosis, ferroptosis, paraptosis, and necroptosis, and their roles in cancer progression and therapeutic response. Complementing these efforts, her group is pioneering a first-in-class targeted protein degradation strategy using AUTOTAC (autophagy-targeting chimera) technology to eliminate oncogenic drivers such as the androgen receptor and its splice variants in castration-resistant prostate cancer.

Collectively, Dr. Kim’s research integrates tumor signaling, microenvironmental crosstalk, metabolic reprogramming, programmed cell death, and targeted protein degradation to uncover fundamental cancer biology and to develop innovative therapeutic strategies for aggressive and treatment-resistant malignancies.

Research description

The long term objective of Dr. Kim’s research is to unveil the molecular and cellular mechanisms by which proteolytic and growth factor signaling networks contribute to tumor progression. Dr. Kim’s laboratory has investigated platelet-derived growth factor (PDGF) isoform-specific signal transduction pathways and their roles in prostate and breast cancer progression. Recently, Dr. Kim’s laboratory showed that tumor-produced PDGF C and D undergo proteolytic activation by the serine proteases uPA and matriptase and mediate stromal reactions, critical for tumor cell invasion and metastasis. The laboratory of Dr. Kim has also investigated the pleiotropic activity of tissue inhibitor of metalloproteinases (TIMP)-1 during cancer progression. Dr. Kim’s recent study identified the tetraspanin member CD63 as the first TIMP-1 binding cell surface protein, which mediates the integrin β1 survival pathway as well as phenotypic changes resembling an epithelial mesenchymal transition (EMT). 

PubMed - my bibliography

 PubMedKimHRC

Education/training

PhD (1989) Northwestern University
Postdoctoral Fellowship (1992) Washington University, St. Louis
 

Teaching and research excellence awards

Wayne State University School of Medicine Teaching Award (2023, 2018, 2001)
Wayne State University School of Medicine Excellence in Research Award (2025,2020, 2002)
Brain Pool Program Award, Korean National Science Foundation (2015)
US Department of Defense Career (1996 – 2000)

Courses taught by Hyeong-Reh Kim, Ph.D.

Fall 2026 (current)

Fall Term 2025

Fall Term 2024

← Return to listing